Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment Reporting Information [Line Items]
Net revenues	$ 5,284	$ 9,296	$ 22,446	$ 36,088
Cost of revenues (excluding amortization of acquired intangible assets)	3,904	3,883	12,700	7,646
Direct expenses	13,904	16,565	47,880	56,143
Segment contribution	(12,524)	(11,152)	(38,134)	(27,701)
Indirect expenses	376	375	1,116	1,377
Loss from operations	(12,900)	(11,527)	(39,250)	(29,078)
Cell Therapy [Member]
Segment Reporting Information [Line Items]
Net revenues	1,592		2,615
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses	4,079	3,496	10,263	12,383
Segment contribution	(2,487)	(3,496)	(7,648)	(12,383)
BioBanking [Member]
Segment Reporting Information [Line Items]
Net revenues	1,448	1,292	4,131	3,857
Cost of revenues (excluding amortization of acquired intangible assets)	220	238	649	952
Direct expenses	365	353	1,121	1,216
Segment contribution	863	701	2,361	1,689
Degenerative Disease [Member]
Segment Reporting Information [Line Items]
Net revenues	2,244	8,004	15,700	32,231
Cost of revenues (excluding amortization of acquired intangible assets)	3,684	3,645	12,051	6,694
Direct expenses	1,358	4,187	7,959	14,385
Segment contribution	(2,798)	172	(4,310)	11,152
Other [Member]
Segment Reporting Information [Line Items]
Net revenues
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses	8,102	8,529	28,537	28,159
Segment contribution	(8,102)	(8,529)	(28,537)	(28,159)
Indirect expenses	376	375	1,116	1,377
Amortization	376	375	1,116	1,377
Total other	$ 376	$ 375	$ 1,116	$ 1,377